Part 1: iRECIST: New Guidelines for Oncology Tumor Assessment - CE



Products

Part 1: iRECIST: New Guidelines for Oncology Tumor Assessment

Part 1: iRECIST: New Guidelines for Oncology Tumor Assessment

Mar 11, 2020 12:00pm ‐ Mar 11, 2020 1:00pm

In oncology clinical trials, assessment of changes in tumor burden is a primary endpoint. For solid tumors, RECIST 1.1 is the established criteria. However, as we move from chemotherapeutic trials into immunotherapeutic trials, a new response to treatment pattern has become evident. A subset of patients to have increased tumor burden that is followed by a clear response or prolonged stabilization of the cancer. iRECIST guidelines have been developed to capture this new response pattern. This presentation, Part 1 of 2 presentations, will introduce you to the history of the iRECIST guidelines, the iRECIST process and how iRECIST is being used in oncology clinical trials. Part 2 will consist of a workshop using hypothetical cases to determine iRECIST responses.

Learning Objectives:

  • Part 1: Understand the history and need for development of the iRECIST guidelines
  • Part 1: Define terms of tumor measurement and objective change in tumor burden in iRECIST
  • Part 2: Review hypothetical cases to determine iRECIST response

Speaker(s):
  • Mary Ricker, MA, RN, Sr. Clinical Research Associate – US Oncology, Merck Research Laboratories